A Study to Evaluate Unintended Prolonged Opioid Use

Overview

About this study

The primary purpose of this study is to identify patient characteristics that are associated with unintended prolonged opioid use (UPUO).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • No use of opioids for 6 months prior to the issuance of the initial opioid prescription.
  • At least 1 dose of the initial opioid prescription was taken.
  • Willingness to participate in all aspects of the study including use of the mobile health platform on their personal smartphone.
  • Patients meeting these inclusion criteria will be further categorized based on CONSORT criteria.

Criteria for the long-term CONSORT category includes:

  • Episodes of opioid prescribing lasting longer than 90 days and including 120 or more total days’ supply or 10 or more prescriptions.

Criteria for the short-term CONSORT category includes:

  • Episodes of opioid prescribing lasting 90 days or less.

Exclusion Criteria:

  • Cancer-associated pain.
  • Concurrent treatment for cancer (e.g., chemotherapy, radiation therapy).
  • Residence in an extended care facility.
  • Mental health disorders that could impede functioning in an ambulatory care setting (e.g., schizophrenia, dementia).
  • Non-English speaking individuals.
  • Although study participation will be limited to adults who own a smartphone, recent data from January 2018 demonstrate 77% of U.S. residents own a smartphone.
  • An iPad will be available for use by adults not wanting to utilize their smartphone, or for those not owning a smartphone.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Hooten, M.D.

Open for enrollment

Contact information:

Brenda Anderson R.N.

(507)255-7157

anderson.brenda@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20460649

Mayo Clinic Footer